Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
NRG Oncology
Emory University
PrECOG, LLC.
Bristol-Myers Squibb
Cedars-Sinai Medical Center
Chinese University of Hong Kong
Nuvectis Pharma, Inc.
Ohio State University Comprehensive Cancer Center
SWOG Cancer Research Network
Samsung Medical Center
Avistone Biotechnology Co., Ltd.
City of Hope Medical Center
The First Affiliated Hospital of Guangzhou Medical University